Predict your next investment

Corporation
shinhaninvest.com

See what CB Insights has to offer

Investments

41

Portfolio Exits

1

Funds

1

Partners & Customers

1

About Shinhan Investment Corp.

Shinhan Investment Corp. is a securities brokerage and investment banking firm.

Shinhan Investment Corp. Headquarter Location

South Korea

82-3772-2220

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Shinhan Investment Corp.

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Shinhan Investment Corp. in 2 CB Insights research briefs, most recently on Oct 23, 2019.

Latest Shinhan Investment Corp. News

SK Bioscience shares slide on slow vaccine development

Jun 20, 2022

SK Bioscience shares slide on slow vaccine development 바로가기 기자명 Kim Chan-hyuk 닫기 SK Bioscience, which once made a strong stock market debut in March last year, is now struggling with sliding the price of its shares on Kospi. Analysts said that to boost the stock price struggling to surpass 100,000 won ($77.4), the company has to present investors with detailed achievements from the vaccine business. SK Bioscience shares have recently declined due to the delay in commercialization of Covid-19 vaccine candidate, SKYCovione, analysts said. As of 11:45 a.m. on Monday, shares of SK Bioscience fell 4.4 percent to 99,400 won, considered too low compared to 362,000 won, a 52-week high recorded on Aug. 17 last year. The poor performance of SK Bioscience stocks is attributed to the delay in the commercialization of a Covid-19 vaccine and the overall jittery investor sentiment amid geopolitical issues and inflation worries. At a news conference early this year, SK Bioscience was confident about commercializing and supplying its Covid-19 vaccine. Ahn Jae-yong, CEO of SK Bioscience, said at the news conference that 36 percent of the world’s population was still unvaccinated, adding that the company was actively studying a booster shot. “By the time Korean people get the fourth Covid-19 vaccination, our vaccine will become a ‘weapon’ to protect Korean people’s health,” Ahn said. However, analysts gave a rather dim outlook for SK Bioscience shares. On Thursday, Shinhan Investment released an analyst report and lowered the target price of SK Bioscience by 33 percent to 121,000 won. Shinhan Investment noted that SK Bioscience must have performed well in the second quarter. As a result, the brokerage predicted that the company’s second-quarter sales and operating profit were estimated to be 140.4 billion won and 64.3 billion won, respectively, up 61 percent and 171 percent quarter-to-quarter. In addition, the report said that the company could improve earnings because it resolved the delay in quality assurance of CDMO for Novavax’s Covid-19 vaccine. However, Shinhan Investment lowered the sales outlook for SK Bioscience's Covid-19 vaccine SKYCovione (pipeline name: GBP510), which is about to arrive in the market because countries have excess stocks of existing Covid-19 vaccines and the lower rate of Covid-19 booster shot vaccination in Korea. Also, SKYCovione may not sell as much as the company had expected, both at home and abroad. The first and second dose vaccination rates in Korea were recorded at 87.4 percent and 86.5 percent, respectively. However, the third dose vaccination rate was 64.6 percent, and for the fourth dose, only 8.3 percent, Shinhan Investment said. The report predicted that the total sales of Covid-19 vaccine developers will also plummet from $63.1 billion in 2022 to $33.6 billion in 2023, to $20.1 billion in 2024. Shinhan Investment estimated SKYCovione’s value at 1.25 trillion won, which is lower than a 1.98 trillion won estimate for SKYpack, a 21-valent pneumococcal vaccine candidate that SK Bioscience is jointly developing with Sanofi. “For a rebound in the stock price, the company needs to show high growth in vaccine sales or specific results of facility expansion and entry into new businesses,” the report added. Vaccine industry officials said it became more difficult to expect rapid revenue growth from Covid-19 vaccines. “We will have to see, but the Covid-19 vaccine market has indeed shrunk,” an official at a vaccine maker said. In the worst scenario, developing a Covid-19 vaccine could even hamper a company’s growth, another official said. “SK Bioscience must be frustrated because Covid-19 vaccine development has become like a government project. It can’t give up in the middle of the development,” an official at a biopharmaceutical firm said. “It is also uncertain how much SK Bioscience’s vaccine will be competitive, compared to Pfizer or Moderna vaccine, in other countries,” he added.

Shinhan Investment Corp. Investments

41 Investments

Shinhan Investment Corp. has made 41 investments. Their latest investment was in GGQ Company as part of their Series A on April 4, 2022.

CBI Logo

Shinhan Investment Corp. Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/13/2022

Series A

GGQ Company

$8.95M

Yes

2

3/2/2022

Series B

Dr.Diary

$12.22M

Yes

1

2/8/2022

Series A

Varram

Yes

1

12/16/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/16/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/13/2022

3/2/2022

2/8/2022

12/16/2021

11/16/2021

Round

Series A

Series B

Series A

Series A

Series A

Company

GGQ Company

Dr.Diary

Varram

Subscribe to see more

Subscribe to see more

Amount

$8.95M

$12.22M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

1

10

10

Shinhan Investment Corp. Portfolio Exits

1 Portfolio Exit

Shinhan Investment Corp. has 1 portfolio exit. Their latest portfolio exit was AptaBio on June 12, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/12/2019

IPO

1

Date

6/12/2019

Exit

IPO

Companies

Valuation

Acquirer

Sources

1

Shinhan Investment Corp. Acquisitions

1 Acquisition

Shinhan Investment Corp. acquired 1 company. Their latest acquisition was Nam An Securities on July 08, 2015.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/8/2015

$99M

Acq - P2P

1

Date

7/8/2015

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acq - P2P

Sources

1

Shinhan Investment Corp. Fund History

1 Fund History

Shinhan Investment Corp. has 1 fund, including Shinhan Consumer New Technology Investment Fund No. 2.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Shinhan Consumer New Technology Investment Fund No. 2

Multi-Stage Venture Capital

Open

1

Closing Date

Fund

Shinhan Consumer New Technology Investment Fund No. 2

Fund Type

Multi-Stage Venture Capital

Status

Open

Amount

Sources

1

Shinhan Investment Corp. Partners & Customers

1 Partners and customers

Shinhan Investment Corp. has 1 strategic partners and customers. Shinhan Investment Corp. recently partnered with TradeStation on June 6, 2014.

Date

Type

Business Partner

Country

News Snippet

Sources

6/16/2014

Licensor

United States

TradeStation Further Expands Asian Market Presence, Partners With Shinhan Investment Corp. to Launch TradeStation 9.5 in Korea

In November 2013 , TradeStation and Shinhan Investment Corp. entered into a strategic alliance granting Shinhan Investment Corp. the exclusive right to market , offer and provide to the Korean investor market industry-leading trading technology powered by TradeStation .

4

Date

6/16/2014

Type

Licensor

Business Partner

Country

United States

News Snippet

TradeStation Further Expands Asian Market Presence, Partners With Shinhan Investment Corp. to Launch TradeStation 9.5 in Korea

In November 2013 , TradeStation and Shinhan Investment Corp. entered into a strategic alliance granting Shinhan Investment Corp. the exclusive right to market , offer and provide to the Korean investor market industry-leading trading technology powered by TradeStation .

Sources

4

Shinhan Investment Corp. Team

1 Team Member

Shinhan Investment Corp. has 1 team member, including current Chief Executive Officer, President, DaeSuk Kang.

Name

Work History

Title

Status

DaeSuk Kang

Chief Executive Officer, President

Current

Name

DaeSuk Kang

Work History

Title

Chief Executive Officer, President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.